Holoclara Announces $16 Million Series A Financing to Advance a Breakthrough Class of Worm-Derived Therapies for Allergic and Autoimmune Disease [Yahoo! Finance]
Hologic, Inc. (HOLX)
Last hologic, inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.hologic.com
Company Research
Source: Yahoo! Finance
Capital to support clinical development of first-in-class, worm-derived medicines for allergies and autoimmune disorders and advancement of discovery engine Peter Barton Hutt, former Chief Counsel for the Food and Drug Administration, joins Holoclara's Board of Directors PASADENA, Calif., June 27, 2024 BUSINESS WIRE )--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergies and autoimmune disorders, today announced the completion of an oversubscribed $16 million Series A financing led by BOLD Capital Partners. Horizons Ventures, Tarrasque, Endurance28, Freeflow Ventures, and a syndicate of leading angel investors also participated in the round. In connection with the financing, Peter Barton Hutt, former Chief Counsel for the Food and Drug Administration (FDA) and currently senior counsel at Covington & Burling LLP, has been appointed to the company's Board of Directors. The capital will be used to progress development of Holoclara
Show less
Read more
Impact Snapshot
Event Time:
HOLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOLX alerts
High impacting Hologic, Inc. news events
Weekly update
A roundup of the hottest topics
HOLX
News
- 3 Medical Instruments Picks to Navigate Industry Challenges [Yahoo! Finance]Yahoo! Finance
- Hologic, Inc. (NASDAQ: HOLX) is now covered by analysts at Stephens. They set an "overweight" rating and a $87.00 price target on the stock.MarketBeat
- U.S. Tattoo Studios & Tattoo Removal Services Market Analysis 2024: Historical Demand 2007-2023, Consumer Demographics 2024-2030, Competitor Profiles by State [Yahoo! Finance]Yahoo! Finance
- Hologic (HOLX) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- UK Hysteroscopy Procedures (CPT Codes) Market Size, Share & Trends Analysis Report 2024-2030 [Yahoo! Finance]Yahoo! Finance
HOLX
Earnings
- 5/2/24 - Beat
HOLX
Sec Filings
- 6/4/24 - Form 4
- 5/30/24 - Form SD
- 5/24/24 - Form 4
- HOLX's page on the SEC website